Sensyne Health and Bayer have announced that Bayer is to become Sensyne Health’s preferred pharmaceutical partner to work together on the development of a national linked patient data capability.
Microsoft, EY, JP Morgan, and Peel Hunt are already in the consortium. Under the terms of the agreement, Bayer will work with Sensyne Health and the consortium members as they develop proposals to scale Sensyne Health’s current network of strategic research agreements with NHS Trusts, aiming to accelerate the discovery and development of new medicines and improve patient care through the analysis of large databases of anonymised patient data, using clinical artificial intelligence.
Sensyne Health and its consortia of experts have the requisite capabilities in clinical AI, computing, data analytics, systems integration, business planning, investment banking and, with the addition of Bayer, the relevant pharmaceutical R&D expertise and capability.
“Access to anonymised national linked patient data heralds a new era in the discovery and development of medicines,” said Kemal Malik, Bayer board member for Innovation. “Through the application of artificial intelligence to large sets of patient information it becomes possible to identify people that are most likely to be at risk of diseases in the future. Importantly, this will allow steps to prevent their progress along that path. Bayer is excited to make its expertise available to develop this capability.”
In keeping with Sensyne Health’s ethical framework and business model, the NHS remains the controller of NHS patient data, and no data is sold or transferred to a third party.
The company acts as a ‘docking station’ for the analysis of anonymised patient data on behalf of its commercial partners under strict ethical control.
